ARPA-H to invest $62 million to develop AI bots that treat heart failure

ARPA-H, the federal agency that funds high-risk, high-reward health research, plans to commit $62.7 million to a program developing artificial intelligence systems capable of directing treatment for heart failure, according to STAT News.

The reporting describes the effort as aiming toward FDA-authorized AI tools that would move beyond diagnostic support into an active role in guiding therapy decisions for patients with heart failure. STAT frames the funding as part of a broader push by the agency to test whether autonomous or semi-autonomous software can take on tasks traditionally reserved for clinicians, particularly the ongoing management of a chronic condition that requires frequent adjustment of medications and monitoring.

STAT’s account, published September 9, 2026, situates the investment within ARPA-H’s mandate to pursue ambitious biomedical technology projects that established funders might consider too speculative. The story does not specify a timeline for when any resulting tools might reach clinical use or complete the FDA authorization process, nor does it name the specific institutions or companies that would receive the funding.

Heart failure affects a substantial patient population and requires ongoing clinical management, which the report cites as part of the rationale for pursuing AI-driven treatment direction rather than diagnostic assistance alone. Further details on the program’s structure, milestones, and participating organizations were not included in the available reporting.